Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 1805793, 9 pages
https://doi.org/10.1155/2018/1805793
Clinical Study

The Effects of Antimicrobial Peptide Nal-P-113 on Inhibiting Periodontal Pathogens and Improving Periodontal Status

1Department of Periodontics, School of Stomatology, China Medical University, Shenyang 110002, China
2Department of Periodontics, Jinan Stomatological Hospital, Jinan 250001, China
3Shenyang Dental Hospital, Shenyang 110002, China
4Institute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu 300, Taiwan

Correspondence should be addressed to Li Lin; nc.ude.umc@ilnil

Received 1 October 2017; Accepted 31 December 2017; Published 15 March 2018

Academic Editor: Carla Renata Arciola

Copyright © 2018 Hongyan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Periodontal disease consists of chronic gingival inflammation characterized by both degradation of the periodontal connective tissue and alveolar bone loss. Drug therapy is used as an auxiliary treatment method in severe chronic periodontitis, aggressive periodontitis, and periodontitis-associated systemic disease. Nal-P-113, a modified antimicrobial peptide, specifically replaces the histidine residues of P-113 with the bulky amino acid β-naphthylalanine, and our previous studies have verified that this novel peptide is not toxic to the human body within a certain concentration range. The objective of the present study was to evaluate the effect of Nal-P-113 on periodontal pathogens and periodontal status in clinical studies. In a split-mouth clinical trial, the pocket depth and bleeding index values tended to decrease in the experimental group compared with those in the control group. SEM results verified that Nal-P-113 restrained the maturation of plaque. Based on real-time polymerase chain reaction, the levels of Fusobacterium nucleatum, Streptococcus gordonii, Treponema denticola, and Porphyromonas gingivalis in subgingival plaque were decreased when the subjects were given Nal-P-113. Bacterial growth curve analysis and a biofilm susceptibility assay verified that Nal-P-113 at a concentration of 20 μg/mL restrained the growth of S. gordonii, F. nucleatum, and P. gingivalis and biofilm formation. Therefore, Nal-P-113 effectively reduces periodontal pathogens and ameliorates periodontal status.